Fluorescent In Situ Hybridization Probe Market Size, Share & Trends Analysis Report By Type (DNA Probes, RNA Probes), By Technology (Quantitative FISH, Multiplex FISH, Conventional FISH), By Application (Cancer Diagnostics, Genetic Diseases, Cytogenetics, Other), By End User (Research, Clinical Use, Companion Diagnostics) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Market Drivers

Technological Advancements in the FISH Technique

A key driver in the FISH probe market is the rapid improvement in technologies, such as multiplex FISH, which make probes more specific, faster and more sensitive. For example, in March 2024, Oxford Gene Technology IP Limited’s Cytocell launched its latest multiplex FISH panel capable of simultaneously detecting multiple chromosomal abnormalities in a single assay, which further reduced processing time while improving sensitivity and specificity.

Market Restraint

High Cost Associated with FISH Assays

A major restraint in the FISH probe market is the high cost associated with the FISH assays, which restricts their adoption across clinical settings. This is especially challenging for complex tissue analyses, where advanced probe design and specialized handling are required. As a result, the expensive nature of these assays slowed widespread implementation, limited market growth, and accessibility of FISH-based diagnostics.

Market Opportunity

Growing Use of Fluorescent In Situ Hybridization (FISH) Probe Market in Hematologic Malignancies

An opportunity in the FISH probe market is its expanding use for hematologic cancers, where chromosomal abnormalities play a critical role in diagnosis and treatment selection. Recently, Empire Genomics and BioDot launched hematology-focused FISH probe panels for multiple myeloma, validated on the BioDot CellWriter S platform. This reflected a strong opportunity for companies to develop disease-specific panels that enhance diagnostic efficiency and automation.

Regional Analysis

The North America region dominated the market with a revenue share of 47.23% in 2025. The growth is attributed to factors such as high adoption of advanced cytogenetic technologies in cancer care, funding from the National Institutes of Health (NIH) for genetic and oncology research, and early regulatory approvals by the U.S. Food and Drug Administration (FDA) for advanced FISH-based diagnostic assays.

The fluorescent in situ hybridization probe market in the U.S. is widely driven by the FDA approvals of FISH companion diagnostics. These approvals make FISH testing mandatory for selecting targeted therapies, which directly increases adoption and expands market size. This regulatory backing ensures sustained demand, fueling consistent market growth and strengthening overall global market growth nationwide.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 8.56% during the forecast timeframe. The growth is attributed to factors such as the adoption of advanced molecular diagnostic techniques, such as FISH, as well as growing awareness about early disease detection. These factors improve access and boost the market size and market growth.

The fluorescent in situ hybridization probe market in China is fuelled by the government's inclusion of FISH-based tests in official clinical guidelines and insurance reimbursement. MOH guidelines in China now require FISH tests for certain blood cancers like myelodysplastic syndromes, CLL, and CML, and a few provincial insurance programs cover the cost of approved FISH probes. These policies raise diagnostic use, expanding market size, and boosting market growth.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

In Europe, the fluorescent in situ hybridization probe market is driven by the strict reimbursement policies that cover FISH testing for non-small cell lung cancer, ensuring wider patient access. Along with this, initiatives, such as the Network Genomic Medicine (NGM) program, strengthen molecular diagnostics, boosting demand, expanding market size, and supporting sustainable fluorescent in situ hybridization probe market growth.

The fluorescent in situ hybridization probe market in the UK is growing due to the NHS Genomic Medicine Service, which includes FISH testing in the National Genomic Test Directory. In addition, government funding through the Genome UK strategy, expansion of regional genomic laboratories, and NHS partnerships with leading diagnostic companies are increasing accessibility. These efforts boost early cancer detection, expand market size, and ensure sustainable fluorescent in situ hybridization probe market growth.

Middle East and Africa Market Insights

The market is growing due to enhanced research and development funding by governments and other organizations, which is fostering the development and adoption of advanced FISH technologies in the region.

The market is growing in South Africa due to increasing private healthcare investments and the expansion of molecular diagnostic laboratories. Several diagnostic chains in Gauteng province started integrating FISH technology to offer faster and more accurate cancer and genetic testing services, boosting regional market adoption.

Latin America Market Insights

The market is growing in Latin America due to increasing collaborations between local research institutions and international biotech companies, which are expanding access to advanced FISH technologies. Joint initiatives in Argentina and Chile facilitated the transfer of FISH-based diagnostic platforms to regional hospitals and laboratories, accelerating market growth.

The market in Argentina is growing due to increasing private sector investment in biotechnology and molecular diagnostics. Several private laboratories in Buenos Aires offered FISH-based cancer and prenatal testing services, expanding access to advanced diagnostics and boosting market demand.

Type Insights

The RNA probes segment is anticipated to grow at a CAGR of 8.97% during 2026-2034. The growth is attributed to the increasing adoption of RNA-based FISH technologies such as single-molecule RNA FISH (smFISH) and multiplex RNA FISH, which enable precise visualization of gene expression at the cellular level.

The DNA probes segment dominated the market in 2025, owing to the widespread adoption of DNA-based assays for detecting chromosomal abnormalities and gene rearrangements, along with their higher specificity, stability, and compatibility with a wide range of diagnostic applications.

Technology Insights

The quantitative FISH segment is expected to dominate the market in 2025 with a revenue share of 36.73%. This growth is attributed to the increasing demand for accurate measurement of telomere length, gene amplification, and chromosomal copy number variations in both clinical diagnostics and research applications.

The multiplex FISH segment is anticipated to register the fastest CAGR of 8.23% during the forecast period, owing to its ability to improve diagnostic efficiency, reduce turnaround time, and enable comprehensive genomic profiling in cancer and genetic research.

Source: Straits Research Analysis

Application Insights

The cancer diagnostics segment dominated the market in 2025, with a revenue share of 44.25%. The growth is attributed to the rising global cancer burden, increasing use of FISH probes for detecting chromosomal abnormalities and gene rearrangements, and the growing preference for companion diagnostics in targeted cancer therapies.

The genetic diseases segment is anticipated to register the fastest CAGR of 8.56% during the forecast period, driven by the rising prevalence of hereditary disorders and growing utilization of FISH assays for prenatal and postnatal genetic screening.

End User Insights

The clinical use segment dominated the market in 2025, accounting for a revenue share of 46.22%, owing to the widespread implementation of FISH testing in hospitals and diagnostic laboratories for accurate disease diagnosis and patient management.

The companion diagnostics segment is expected to register the fastest CAGR growth of 9.07%, owing to the rising use of FISH-based assays for therapy selection, and growing collaborations between diagnostic developers and pharmaceutical companies to co-develop targeted treatment solutions.